US DNA Synthesis Market Size Likely to Grow at a CAGR of 19.57% By 2034

Market Size and Growth

As per the US DNA Synthesis Market size analysis conducted by the CMI team, the US DNA synthesis market is expected to record a CAGR of 19.57% from 2025 to 2034. In 2025, the market size was USD 3.73 Billion. By 2034, the valuation is anticipated to reach USD 18.67 Billion.

Overview

As per the industry experts at CMI, the U.S. DNA synthesis market is poised to witness a whopping CAGR during the forecast period. This could be attributed to robust demand for personalized medicine, synthetic biology, and advanced research, especially in diagnostics and gene therapy. The key influencers include visible investments in R&D activities and pharmaceutical and biotech infrastructure. The U.S. is at the forefront with regard to genomic innovation, thanks to government funding and emphasis on the development of new applications for tailor-made DNA sequences.

Key Trends & Drivers

• Demand for Personalized Medicine to Determine Growth: The exponential demand for custom DNA in precision diagnostics as well as treatments for chronic and genetic diseases is fueling the U.S. DNA synthesis market. Also, synthetic DNA is increasingly being asked for for advanced research, development of drugs, and new therapeutic approaches such as gene therapy. Besides, there are innovations witnessed in gene editing. AI-driven design tools are also in place, which facilitate more scalable and precise DNA synthesis.

• Global Leadership of the U.S. in Healthcare to Catalyze the Market: The U.S. has been dominating the market for DNA synthesis due to its huge network of research institutions, biotechnology companies, and academic centers. Noticeable healthcare spending has also created an environment conducive to the market. Contract research organizations and biopharmaceutical companies are amongst the notable users if DNA synthesis services, thereby driving drug development and innovation.

Report Scope

SWOT Analysis

• Strengths: A robust biotechnology infrastructure extends support to the U.S. DNA synthesis market. Plus, rising demand from diagnostic, pharmaceutical, and academic sectors catalyzes the DNA synthesis market. There are also continual improvements in automation, gene editing, and DNA synthesis technologies, which are making custom sequences more accessible and affordable.

• Weaknesses: DNA synthesis could be costly, especially for complex or large-scale sequences. Also, synthesizing precise, long DNA sequences stays technically challenging. This could prove to be a weakness for new entrants, as they will have to shell out extra to employ experts in the field.

• Opportunities: The U.S. DNA synthesis market has opportunities to expand the usage of DNA synthesis technology in the development of DNA-based treatments and gene therapies. Also, an increased reliance is being witnessed by diagnostic centers and research institutes regarding custom DNA for advanced biomedical research and diagnostic tools.

• Threats: Risk of synthetic DNA’s accidental release may invite regulatory scrutiny. Also, fierce competition amongst DNA synthesis service providers may make the research institutes and diagnostic centers switch to alternative synthesis methods.

List of the prominent players in the US DNA Synthesis Market:

• Charles River Laboratories
• VGXI Inc.
• Danaher (Aldevron)
• Thermo Fisher Scientific
• Lonza
• GenScript
• Twist Bioscience
• AGC Biologics
• Catalent
• Eurofins Genomics
• Others

The US DNA Synthesis Market is segmented as follows:

By Service Type

• Oligonucleotide Synthesis
• Type
• Standard Oligonucleotide Synthesis
• Custom Oligonucleotide Synthesis
• Length
• Less than 50 nt
• 51-100 nt
• 101-150 nt
• More than 150 nt
• Gene Synthesis
• Type
• Custom Gene Synthesis
• Gene Library Synthesis
• Length
• Less than 500 nt
• 501-1000 nt
• 1001-1500 nt
• 1501-2000 nt
• 2001-2500 nt
• More than 2500 nt

By Application

• Research & Development
• Oligonucleotide Synthesis
• PCR
• NGS
• CRISPR
• Cloning and Mutagenesis
• Others
• Gene Synthesis
• Synthetic Biology
• Vaccine Development
• Genetic Engineering
• Others
• Diagnostics
• Therapeutics
• RNAi Therapies
• Antisense Oligonucleotide-based Therapies
• Others

By End-use

• Biopharmaceutical & Diagnostics Companies
• Academic & Research Institutes
• Contract Research Organizations

[embedsocial_reviews id=”d4ae80cffae3d938f997111953699a733c8e6f99″]